International journal of clinical oncology · 2026
Secondary primary tumors following iodine-125 low-dose-rate brachytherapy for localized prostate cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Niwa Kojiro, Iinuma Koji, Nakano Masahiro, Tomioka Masayuki, Ito Masaya, Mori Takayuki, Kawase Kota, Taniguchi Tomoki, Tobisawa Yuki, Nakane Keita, Matsuo Masayuki, Koie Takuya
Аннотация
BACKGROUND: Low-dose-rate brachytherapy with iodine-125 (LDR-BT) is an established curative radiation treatment modality for localized prostate cancer (PCa). This study aimed to evaluate the long-term incidence of secondary primary tumors (SPTs) following LDR-BT in Japanese patients with localized PCa and identify predictive factors associated with SPTs.
METHODS AND MATERIALS: We retrospectively reviewed the clinical records of 478 consecutive patients with localized PCa who underwent LDR-BT at the Gifu University Hospital. This study's primary endpoint was SPTs incidence, including bladder and rectal/anal cancers. The secondary endpoint was the identification of risk factors for LDR-BT that predicted SPTs development.
RESULTS: After a median follow-up period of 105 months, SPTs developed in 13 patients (2.7%). Bladder cancer and rectal/anal canal cancer were observed in seven (1.5%) and six (1.3%) patients, respectively. Multivariate analysis showed that a biologically effective dose (BED) ≥ 197 Gy was associated with increased risk of SPTs (hazard ratio 4.145; 95% confidence interval 1.108-15.498; p = 0.035).
CONCLUSIONS: The incidence of SPTs following LDR-BT was relatively low. In multivariate analysis, BED ≥ 197 Gy may be associated with an increased risk of SPT occurrence. Adequate tumor control can be achieved through appropriate radiation dose administration; carefully planned long-term follow-up may be beneficial for SPTs early detection.
METHODS AND MATERIALS: We retrospectively reviewed the clinical records of 478 consecutive patients with localized PCa who underwent LDR-BT at the Gifu University Hospital. This study's primary endpoint was SPTs incidence, including bladder and rectal/anal cancers. The secondary endpoint was the identification of risk factors for LDR-BT that predicted SPTs development.
RESULTS: After a median follow-up period of 105 months, SPTs developed in 13 patients (2.7%). Bladder cancer and rectal/anal canal cancer were observed in seven (1.5%) and six (1.3%) patients, respectively. Multivariate analysis showed that a biologically effective dose (BED) ≥ 197 Gy was associated with increased risk of SPTs (hazard ratio 4.145; 95% confidence interval 1.108-15.498; p = 0.035).
CONCLUSIONS: The incidence of SPTs following LDR-BT was relatively low. In multivariate analysis, BED ≥ 197 Gy may be associated with an increased risk of SPT occurrence. Adequate tumor control can be achieved through appropriate radiation dose administration; carefully planned long-term follow-up may be beneficial for SPTs early detection.